Work

A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors

Year: 2017

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-017-0467-7

Authors: Janice M. Mehnert, Gerald Edelman, Mark Stein, Heather Camisa, Joanne Lager, Jean-François Dedieu, Anne-Frédérique Ghuysen, Jyoti Sharma, Li Liu, Patricia M. LoRusso

Institutions: Rutgers Cancer Institute, Sanofi (France), Sanofi (United States), Yale University

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Amgen, Sanofi, Merck Sharp and Dohme

OpenAlex ID: W2607479181

FWCI: 0.292

Cites: 24

Cited by: 14

Related to: 10